Investor Compass Takeaway Oral Wegovy expands the total GLP-1 market India remains a volume led adoption story Front end formulations = crowded, margin pressure Backend GLP-1 enablers = cleaner, more predictable compounding Injectables remain structurally relevant even as oral grows Sources: Systematix & Company filings No Buy/Sell recommendation #StocksInFocus #StocksToWatch #GLP1 #shaily US approves Oral GLP-1 | Will This Change the GLP-1 Game | Who Benefits in India
2016;7:e2106
Check out our list of the best protein powders for weight loss
The dual action on diabetes and obesity has now positioned GLP-1 agonists in a prominent position for addressing two of the most pressing health challenges of this generation (Chothave et al., 2024)
Similar to the acute phase of C-19, L-C19 also depends on a series of risk factors such as sex, age, co-morbidities, severity of C-19, hospitalization and its duration, C-19 sequelae, the treatment applied in the acute phase, vaccination, as well as lifestyle
Nocciole e arachidi
